STOCK TITAN

Illumina, Inc. - ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Illumina, Inc. (NASDAQ: ILMN) is at the forefront of genomic technology, providing innovative tools and services to analyze genetic material. With a primary focus on DNA sequencing and array-based technologies, Illumina serves a diverse range of markets including life sciences, oncology, reproductive health, and agriculture. Over 90% of its revenue stems from sequencing instruments, consumables, and services, with the remainder coming from microarrays used in genetic screening for consumer and agricultural applications. Illumina's technology enables high-throughput whole genome sequencing, which is essential for large-scale genomic studies, as well as lower throughput tools for specific applications such as viral and cancer tumor screening.

Recent advancements at Illumina include the upcoming release of their first quarter 2024 financial results, showcasing significant improvements in both gross and non-GAAP operating margins. The company's innovative solutions continue to drive sequencing activity globally, despite challenging economic conditions. Illumina's NovaSeq X Sequencing System exemplifies their cutting-edge research and development efforts, demonstrating the company's commitment to delivering superior technology for genomic analysis.

In the oncology domain, Illumina's Whole-Genome Sequencing (WGS) and Comprehensive Genomic Profiling (CGP) are setting new standards for cancer diagnostics and treatment. By collaborating with leading institutions and pharmaceutical companies, Illumina is enhancing the scientific understanding of cancer biology and developing advanced assays for Molecular Residual Disease (MRD) detection. These efforts are crucial in precision oncology, enabling early detection and personalized treatment strategies.

Illumina is also committed to expanding access to genomic testing. Through initiatives like The Future Is Bright and partnerships with educational institutions, the company is fostering the next generation of scientists. Their volunteer programs and educational outreach aim to increase genomic literacy and inspire students to pursue careers in STEM fields.

Furthermore, Illumina's ongoing collaboration with GRAIL, Inc., a wholly-owned subsidiary focused on early cancer detection, highlights the company's dedication to transformative healthcare solutions. Despite regulatory challenges, Illumina remains steadfast in its mission to unlock the power of the genome and improve human health.

Stay updated with Illumina's latest developments and financial performance by visiting their website and connecting on social media platforms like X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Rhea-AI Summary

Illumina (NASDAQ: ILMN) has announced a Strategy Update presentation scheduled for August 13, 2024, starting at 8:00am Pacific Time. This event will feature presentations from Illumina's executive team, followed by a Q&A session.

Interested participants can access the webcast through the Events & Presentations section of Illumina's Investor Relations website. Pre-registration is recommended and can be done on the company's website or via a provided registration link. A replay of the event will be available on the Investor Relations website for at least 30 days after the presentation.

This update comes following a previous announcement on June 24, highlighting Illumina's commitment to keeping investors and stakeholders informed about the company's future plans and strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences
-
Rhea-AI Summary

Illumina Ventures, a leading genomics and precision health venture firm, has announced the addition of two new advisors: Dr. Timothy Stenzel and Jerry Steiner. Dr. Stenzel, former director of the FDA's Office of In Vitro Diagnostics, brings extensive experience in molecular diagnostics and regulatory affairs. Jerry Steiner, former executive VP of Sustainability at Monsanto, offers deep insights into agricultural biotech and sustainability.

These appointments strengthen Illumina Ventures' expertise in navigating complex regulatory environments and identifying opportunities in sustainable agriculture through genomics. The firm aims to support innovative diagnostics companies and apply genomics to address global climate change challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
-
Rhea-AI Summary

Illumina is set to announce its second quarter 2024 financial results on August 6, 2024, following the market close. The announcement will be followed by a conference call at 1:30 pm PT (4:30 pm ET) hosted by CEO Jacob Thaysen and CFO Ankur Dhingra. The call will be accessible via Illumina's Investor Info section on their website or by dialing specific numbers provided, with a replay available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Rhea-AI Summary

Illumina announced the expansion of its iHope China program, which will provide free genetic testing to 1800 families with rare diseases in 2024. Launched in 2022, the program collaborates with key hospitals and supports clinicians with training in genetic disease diagnosis. By mid-May 2024, iHope China had assisted 513 families and plans to cover 13 provinces and cities by the year's end. The program aims to improve early diagnosis and treatment of rare diseases, supported by national policies and technological advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
-
Rhea-AI Summary

Illumina (NASDAQ: ILMN) announced its acquisition of Fluent BioSciences, effective July 9, 2024. Fluent BioSciences specializes in highly differentiated single-cell analysis technology. This acquisition enhances Illumina's multiomics capabilities by integrating Fluent's innovative PIPseq™ V technology, which offers scalable and accessible single-cell analysis without costly instrumentation. Illumina aims to deliver comprehensive multiomics solutions, fostering faster and more economical research. The acquisition is funded with cash on hand, and Fluent's team will join Illumina to develop end-to-end solutions for single-cell analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
-
Rhea-AI Summary

Illumina has successfully completed the spin-off of GRAIL, which will start trading independently on Nasdaq under the ticker 'GRAL' on June 25. Illumina will retain a 14.5% share in GRAIL and continue supporting it with its sequencing technology. Additionally, Illumina announced it will release its Q2 2024 earnings results on August 6 and provide a strategy update on August 13. The divestiture process included a distribution of 85.5% GRAIL shares to Illumina shareholders and a $750 million credit facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary

Illumina recently highlighted the contributions of four employees—Samuel Strom, Shyamal Mehtalia, Elyse Hartnett, and Ahmet Badur—whose work significantly impacts genomics and patient care. Strom, a principal scientist, developed targeted algorithms for genetic diseases. Mehtalia, a principal software engineer, collaborates with customers to create innovative solutions like the NextSeq 2000 System in marine research. Hartnett, an oncology product manager, spearheaded partnerships to advance oncology therapy options. Badur, an innovation engineering manager, improved product packaging for sustainability and efficiency. Their stories showcase Illumina's dedication to innovation, collaboration, and ethical standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary

On June 12, 2024, Illumina, a global genomics leader, released a video featuring its employees sharing their motivations for working at the company. The video highlights Illumina's mission to use genomics for the greater good through transformative innovations in various fields including oncology, reproductive health, genetic diseases, microbiology, agriculture, and forensic science. The company emphasizes a unified commitment to its mission across all departments. For further details, visit Illumina's careers site or their profile on 3blmedia.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
Rhea-AI Summary

Illumina launched DRAGEN v4.3, an advanced software version for analyzing next-generation sequencing data. DRAGEN v4.3 introduces innovative features like a prebuilt pangenome from 128 samples across 26 ancestries, reducing ancestry bias and improving accuracy. The software also includes machine learning enhancements for mosaic variant calling, specialized variant discovery callers, and AI-powered annotations using SpliceAI and PrimateAI-3D. These upgrades aim to provide comprehensive and accurate genomic insights. The Human Pangenome Reference Consortium (HPRC) supports these efforts, having delivered 47 high-quality assemblies for diverse ancestries. Broad Clinical Labs confirmed DRAGEN v4.3's accuracy and speed in variant calling and clinical whole-genome research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
Rhea-AI Summary

Illumina has integrated its new XLEAP-SBS™ chemistry into all reagents for its NextSeq™ 1000 and NextSeq 2000 NGS instruments. This update promises faster run times, enhanced quality, and higher output at a lower cost per kit.

In March, Illumina launched the P4 flow cell for NextSeq 2000, delivering up to 540 Gb of output. Now, the company confirms availability of XLEAP-SBS P1, P2, and P3 flow cells, further advancing sequencing capabilities.

Early-access users report notable improvements in read quality, stability, and turnaround times, with a 20% reduction in sequencing time. These enhancements facilitate larger NGS projects and broader adoption of multiomic approaches without increasing budgets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none

FAQ

What does Illumina, Inc. specialize in?

Illumina specializes in innovative tools and services for DNA sequencing and array-based technologies, serving various markets such as life sciences, oncology, reproductive health, and agriculture.

What are Illumina's main revenue sources?

Over 90% of Illumina's revenue comes from sequencing instruments, consumables, and services. The remainder is generated from microarrays used in genetic screening for consumer and agricultural applications.

How is Illumina contributing to cancer research?

Illumina contributes to cancer research through Whole-Genome Sequencing (WGS) and Comprehensive Genomic Profiling (CGP), which are critical for cancer diagnostics and personalized treatment strategies. They also collaborate with leading institutions and pharmaceutical companies for advanced assay development.

What are some recent achievements of Illumina?

Recent achievements include the development and market release of the NovaSeq X Sequencing System, advancements in Molecular Residual Disease (MRD) detection, and financial performance improvements highlighted in their Q1 2024 report.

What is the role of GRAIL in Illumina's operations?

GRAIL, a wholly-owned subsidiary of Illumina, focuses on early cancer detection using next-generation sequencing and advanced data science. Despite regulatory challenges, Illumina aims to divest GRAIL efficiently while maintaining focus on their core business.

How is Illumina expanding genomic literacy?

Illumina expands genomic literacy through educational initiatives like The Future Is Bright, which involves employee volunteers engaging with students to inspire them to pursue STEM careers.

Where can one find Illumina's latest news and updates?

Illumina's latest news and updates can be found on their official website www.illumina.com and through their social media profiles on platforms like X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

What types of genomic analysis does Illumina technology support?

Illumina technology supports high-throughput whole genome sequencing for large organisms and lower throughput tools for specific applications like viral and cancer tumor screening. Their microarrays also enable cost-effective genetic screening.

What educational programs does Illumina offer?

Illumina offers educational programs such as The Future Is Bright and Genomics 101, which aim to increase genomic literacy and inspire students through hands-on learning and career panels.

How is Illumina addressing the global cancer burden?

Illumina is addressing the global cancer burden by developing advanced genomic technologies for early cancer detection and precision oncology. Their collaboration with GRAIL and other institutions enhances the scientific understanding and treatment of various cancer types.

Illumina, Inc.

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

18.24B
159.30M
0.27%
95.59%
3.22%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO